Results 111 to 120 of about 125,674 (260)

Leveraging 3D Molecular Spatial Visual Information and Multi‐Perspective Representations for Drug Discovery

Advanced Science, Volume 13, Issue 2, 9 January 2026.
A deep learning framework called MolVisGNN is proposed to fuse 3D molecular visual information of drugs with multi‐source features, which proves the importance of 3D molecular visual information of drugs and the advancedness of this model in the field of drug discovery, and provides a reference for how to more comprehensively express small molecule ...
Zimai Zhang, Xi Zhou, Yujie Qi, Xiaobo Zhu, Xun Deng, Feng Tan, Yuan Huang, Lun Hu, Zhuhong You, Pengwei Hu   +9 more
wiley   +1 more source

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study

Scientific Reports, 2014
BCR-ABL tyrosine kinase plays a major role in the pathogenesis of chronic myeloid leukemia (CML) and is a proven target for drug development. Currently available drugs in the market are effective against CML; however, side-effects and drug-resistant ...
H. N. Banavath, O. P. Sharma, Muthuvel Suresh Kumar, R. Baskaran   +3 more
semanticscholar   +1 more source

Tofacitinib Use in a Patient With Rheumatoid Arthritis and Polycythemia Vera: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction, whereas polycythemia vera (PV) is a myeloproliferative neoplasm driven by the Janus kinase (JAK)2 V617F mutation, resulting in erythrocytosis and increased thromboembolic risk.
Milan Bogojevic, Rifat Medjedovic, Milica Markovic, Nikola Bakic, Dragana Pravilovic Lutovac   +4 more
wiley   +1 more source

Gut microbiota-derived propionate reduces cancer cell proliferation in the liver [PDF]

, 2012
Peer reviewedPublisher ...
A Everard, A M Neyrinck, AJ Brown, AS Neish, BF Hinnebusch, BL Pool-Zobel, C Cherbut, C Daubioul, C Sundstrom, E Le Poul, E M Dewulf, F Guarner, G G Muccioli, G Tolhurst, HS Taper, J Bray, J Busserolles, J C Martin, J Verrax, K P Scott, KM Maslowski, L B Bindels, LB Bindels, M Aoyama, M Montillo, MA Cox, MA Vinolo, N M Delzenne, NG Kondegowda, O Feron, P Buc Calderon, P D Cani, P Louis, P Porporato, P Sonveaux, P Sonveaux, PD Cani, PD Cani, R Alric, R Ren, S Siavoshian, T Lee, W Fiskus, Y Tang, Y Tang, Y Wang, YH Hong   +46 more
core   +1 more source

Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran, Harshal Mamlekar, Souvik Saha, Rajesh Kashyap, Sanjeev Yadav, Khaliqur Rahman, Ruchi Gupta, Mona Vijayaran, Manish Singh, Dinesh Chandra   +9 more
wiley   +1 more source

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

Molecular Cancer, 2012
Background Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I ...
Fei Fei, Lim Min, Schmidhuber Sabine, Moll Jürgen, Groffen John, Heisterkamp Nora   +5 more
doaj   +1 more source

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response [PDF]

, 2011
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with ...
BENDIT, Israel, DELAMAIN, Marcia Torresan, LORAND-METZE, Irene, MACHADO, Melissa Pereira, PAGNANO, Katia Borgia Barbosa, PEREIRA, Noemi Farah, SOUZA, Cármino Antonio de, TOMAZ, Juarez Pires, VIGORITO, Afonso Celso   +8 more
core   +2 more sources

Acute lymphoblastic B‐cell leukemia or CAR‐T cell related skin changes – a relevant diagnostic challenge

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Farzan Solimani, Amrei Dilling, Konrad Heisterkamp, Frederik Damm, Olaf Penack, Christian Oberender, Philipp Le‐Coutre, Martina Rudelius, Kamran Ghoreschi, Alexander Nast   +9 more
wiley   +1 more source

Predictors of Response to Imatinib Therapy and Long‐Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Chronic myeloid leukaemia (CML) is an infrequent myeloproliferative neoplasm in the paediatric population as compared to adults. Despite vast progress in understanding the disease biology and therapy of CML‐chronic phase (CML CP), the applicability of risk scoring systems in practice and prognostic factors in children remain grey ...
Souvik Saha, Sanjeev Yadav, Manish Kumar Singh, Khaliqur Rahman, Dinesh Chandra, Ruchi Gupta, Rajesh Kashyap   +6 more
wiley   +1 more source

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Haematologica, 2008
The BCR-ABL K247R change is based on a rare single nucleotide polymorphism occurring likewise in healthy controls and non-hematologic cell types. Despite its juxtaposition to the P-loop, functional analysis showed no alteration compared to non-mutated ...
Thomas Ernst, Jana Hoffmann, Philipp Erben, Benjamin Hanfstein, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller   +7 more
doaj   +1 more source